04
Explore biomarker testing for Alzheimer’s disease
One of the major advances in Alzheimer’s disease over the past two decades has been the development and validation of biomarkers.1 What impact will biomarker testing have on the early detection of Alzheimer’s disease? What will it mean for patients?
3 biomarker types:
amyloid beta, hyperphosphorylated tau, and neurodegeneration or neuronal injury2
>80% sensitivity and specificity
is considered optimal for an Alzheimer’s disease biomarker3
‘There’s this really big window of opportunity to detect people who are on a trajectory to dementia.’
A/Prof Peter van Wijngaarden
Discover more
MARKING THE WAY TOWARDS EARLY DIAGNOSIS
Biomarkers have the potential to push the limits of early detection into uncharted territory. On this MindChangers podcast episode, Prof Chris Rowe and Dr Qiao-Xin Li discuss how PET imaging and CSF biomarker testing are about to change the diagnosis of Alzheimer’s disease.
Login Required
GUIDELINES FOR THE USE OF BIOMARKERS
An overview of how international guidelines and expert working groups are updating their recommendations to include the use of fluid and imaging biomarkers for the diagnosis of mild cognitive impairment and Alzheimer’s disease.
Login Required
IS A SIMPLE TEST A STEP CLOSER?
Innovative new technologies have the potential to make biomarker testing for Alzheimer’s disease quicker, easier and less invasive for patients. A/Prof Peter van Wijngaarden and Prof Ashley Bush discuss what is on the horizon in this episode of the MindChangers podcast.
Login Required
LEVERAGING BIOMARKERS FOR AN EARLIER DIAGNOSIS
From neuroimaging to CSF and blood-based biomarkers, Prof Chris Rowe discusses the future use of biomarkers for aiding the early diagnosis of Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2020.
Login Required
‘Through the use of biomarkers, we’re getting a much more comprehensive picture of what happens in Alzheimer’s disease.’
A/Prof Michael Woodward
References: 1. Khoury R, Ghossoub, E. Neuropsychiatry. 2019;1(100005):1–6. 2. Jack CR Jr et al. Alzheimers Dement. 2018;14(4):535–62. 3. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19(2):109–16.